Karyopharm FY2025 total rev $146M; XPOVIO $115M; net loss $196M; FY2026 guidance $130-150M; key trial readouts in 2026

Karyopharm Therapeutics Inc.

2025-FY EPS reported -$17.93 vs consensus -$2.03 ▼ miss (-781.4%)

FY2025 total revenue $146.1M (up from $145.2M); U.S. XPOVIO net product revenue $114.9M (up from $112.8M).
FY2025 net loss $196.0M ($17.93/share) vs $76.4M prior year, driven by $62.4M loss on debt extinguishment.
Cash, cash equivalents and investments $64.1M at Dec 31, 2025 vs $109.1M at Dec 31, 2024; runway into Q2 2026.
FY2026 guidance: total revenue $130-150M, XPOVIO net product $115-130M, R&D+SG&A $230-245M.
Phase 3 SENTRY myelofibrosis trial top-line data expected March 2026; Phase 3 endometrial cancer data mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.